FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/VRTX
icon
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Vertex Pharmaceuticals Incorporated (VRTX) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Vertex Pharmaceuticals (VRTX) trades at $540, up 1.95% with strong technical momentum and bullish moving averages. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b results for inaxaplin kidney disease treatment highlight pipeline expansion. Revenue grew to $12B in 2025 with $4B net income recovery from 2024's loss.
Outlook remains positive with 85% analyst buy ratings and $573.50 consensus target. Key catalysts include regulatory decisions on new products and continued CF franchise strength. Risks include pipeline execution, competition in gene therapy, and reliance on CF treatments. The stock offers growth potential but requires monitoring of clinical developments.
Read full analysis

Key Stats

  • Market Cap
    $136.87B
  • Volume
    1,536,463
  • Sector
    Health
  • 52W High
    $559.41
  • 52W Low
    $409.47
  • Typical Hold Time
    122 Days
  • Enterprise Value
    $130.99B
  • Div Yield
    -
  • Trading Activity
    77% Sell | 23% Buy
$559.41
52W Low: $409.47
07 Nov 2025
52W High: $559.41
30 Oct 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $409.47 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Most Recent News

Content is generated by Aura AI

UVIX ETF jumps 28% amid volatility but is risky for long-term investors due to value loss.

The UVIX ETF, which offers 2x leveraged exposure to VIX futures, surged over 28% during a day of extreme market volatility. However, it is not suitable for long-term holding because of significant value erosion caused by beta slippage and the roll ef...

Market News
5 hours ago
Seeking Alpha
Bearish
news icon
UVIX ETF jumps 28% amid volatility but is risky for long-term investors due to value loss.

Equal-weight S&P 500 outperforms cap-weighted by 5.85% in October, biggest swing since 1990.

In October, the equal-weighted S&P 500 index outperformed the cap-weighted S&P 500 by 5.85 percentage points, reversing September's trend where it had lagged by 4.61 points. This 10.46-point swing is the largest monthly shift between these two indexe...

Market News
5 hours ago
Seeking Alpha
Bullish
news icon
Equal-weight S&P 500 outperforms cap-weighted by 5.85% in October, biggest swing since 1990.

Bonterra Energy raises 2026 production guidance by 400 BOEPD after strong Charlie Lake results

Bonterra Energy has increased its 2026 production guidance by 400 barrels of oil equivalent per day (BOEPD) due to strong results from its Bonanza Charlie Lake development and an increase in its working interest from 90% to 100%. The company also add...

Market News
6 hours ago
Seeking Alpha
Bullish
news icon
Bonterra Energy raises 2026 production guidance by 400 BOEPD after strong Charlie Lake results
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $136.87B
  • Volume
    1,536,463
  • Sector
    Health
  • 52W High
    $559.41
  • 52W Low
    $409.47
  • Typical Hold Time
    122 Days
  • Enterprise Value
    $130.99B
  • Div Yield
    -
  • Trading Activity
    77% Sell | 23% Buy
$559.41
52W Low: $409.47
07 Nov 2025
52W High: $559.41
30 Oct 2026

Track Vertex Pharmaceuticals Incorporated (VRTX) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Vertex Pharmaceuticals Incorporated has traded between a low of $409.47 and a high of $559.41, highlighting its annual price range. Buy and sell Vertex Pharmaceuticals Incorporated shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!